The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| RDHL | -79.14% | -99.98% | -82.18% | -100% |
| S&P | +14.5% | +93.32% | +14.09% | +358% |
RedHill Biopharma Ltd. develops medicines for gastrointestinal and infectious diseases. It operates through Commercial Operations, and the Research and Development segments. The Commercial Operations segment covers all areas relating to the commercial sales and is being performed by the subsidiary in the U.S. The Research and Development segment includes the study and licensing of therapeutic candidates. Its products include Talicia, Movantik, and Aemcolo. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.
The company's Opaganib might have a promising future, after all.
A clinical failure is sending shareholders to the exits this morning.
Currently no data to display
Currently no data to display.
Currently no data to display.
| Metric | YoY Change |
|---|
RDHL earnings call for the period ending September 30, 2020.
RDHL earnings call for the period ending June 30, 2020.
RDHL earnings call for the period ending March 31, 2020.
RDHL earnings call for the period ending December 31, 2019.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
